18
Nov
2021
Califf Gets FDA Nod, Novo Acquires Dicerna, & a Shrewd Investment in Pittsburgh
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Nov
2021
Chroma Medicine Secures $125m to Edit the Epigenome
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Nov
2021
A Trek in the Himalayas for Cancer Research
The biotech community can do extraordinary things when fixated on a goal. Like curing cancer. I’m excited to announce today that I’m taking a team of biotech leaders on a mission to raise $1 million for cancer research at Fred Hutch. This group will come together on a trek to Everest Base Camp. It’s a legendary hike in the Himalayas... Read More
11
Nov
2021
Pfizer’s Game-Changer, Moderna-NIH Feud Goes Public, & Genomics England Ends Dx Odysseys
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Nov
2021
A Remarkable Life in Science: David Baltimore on The Long Run
Today’s guest on The Long Run is David Baltimore. David is one of the most accomplished biomedical scientists – and scientific citizens — of the past 50 years. He recently won Lasker~Koshland Award for Special Achievement. The award was granted “for the breadth and beauty of his discoveries in virology, immunology, and cancer; for his academic leadership; for his mentorship... Read More
4
Nov
2021
The Vaccine Pile-Up, Regeneron Crushes It, CF Foundation Bets on Flagship Combos
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Nov
2021
CF Foundation Invests up to $110M in Flagship Unit to Combine Technologies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Oct
2021
Pfizer Vaccine OK’d for Kids, Merck Ensures Global Access, and Maraganore Passes Torch
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Oct
2021
Young Biotech Entrepreneurs Finding Community: Tony Kulesa on The Long Run
Today’s guest on The Long Run is Tony Kulesa. Tony is the co-founder of Boston-based Petri. It’s a seed and pre-seed investor in biotech startups. But that doesn’t quite fully describe it. It’s also a community for young founders trying to figure out how to get new enterprises off the ground, and connected with a network of seasoned entrepreneurs who... Read More
26
Oct
2021
DNA Script Snags $165M to Build Up Benchtop DNA Synthesis Market, Technology
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Oct
2021
Biogen’s Face-plant, an Interchangeable Humira, & Boosters OK’d
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Oct
2021
Califf Back at FDA? Moderna’s Booster Slam Dunk, & the Vaccine Equity Debate
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Oct
2021
Reimagining DNA Sequencing With Long Reads: Christian Henry on The Long Run
Today’s guest on The Long Run is Christian Henry. Christian is the CEO of Menlo Park, Calif.-based PacBio. It makes DNA sequencing instruments that are used by scientists around the world. The company has long toiled in the shadow of the market leader – some would say monopolist in DNA Sequencing – Illumina. PacBio was way overhyped in its early... Read More
7
Oct
2021
Collins Exits NIH; WHO Backs GSK Malaria Vaccine; RA, MPM, Atlas Reload
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Oct
2021
Neumora Secures $500M, Amgen Deal, in Quest for Precision Neuroscience R&D
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Oct
2021
Exo Pockets $78M to Make Small Molecules Against Exosite Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Sep
2021
Merck Buys Acceleron, Regeneron Antibody Saves Lives, & Moderna Invests in Cambridge
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Sep
2021
Expansion Snags $80M to Make Small Molecules Against RNA Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Sep
2021
Sequencing Genomes of Indigenous Populations: Keolu Fox on The Long Run
Today’s guest on The Long Run is Keolu Fox. Keolu is an assistant professor at UCSD with a fascinating mix of interests. He’s a Native Hawaiian, and got his PhD in genome sciences from the University of Washington. He’s now taking that mix of life experience and scientific training, and putting it to work on projects that sequence the DNA... Read More
23
Sep
2021
J&J Bounces Back, Illumina-Grail Scrutiny, & AZ’s HER-2 ADC Triumph
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.